Grauers Wiktorin, Hanna http://orcid.org/0000-0002-4412-5695
Nilsson, Malin S. http://orcid.org/0000-0002-0981-2617
Kiffin, Roberta http://orcid.org/0000-0002-4058-1327
Sander, Frida Ewald http://orcid.org/0000-0002-9726-6344
Lenox, Brianna http://orcid.org/0000-0001-8681-9153
Rydström, Anna http://orcid.org/0000-0002-0429-3889
Hellstrand, Kristoffer http://orcid.org/0000-0002-6617-5976
Martner, Anna http://orcid.org/0000-0002-6598-5221
Funding for this research was provided by:
Vetenskapsrådet (2016-01928)
The Swedish state via the ALF agreement (ALFGBG-724881)
Cancerfonden (CAN 2016/351)
Svenska Sällskapet för Medicinsk Forskning
The Hasselblad Foundation
Article History
Received: 11 May 2018
Accepted: 26 September 2018
First Online: 12 October 2018
Compliance with ethical standards
:
: Authors Hanna Grauers Wiktorin, Frida Ewald Sander, Anna Martner, and Kristoffer Hellstrand hold issued or pending patents protecting the use of histamine and/or α-PD-1/α-PD-L1 therapy in cancer treatment. Kristoffer Hellstrand was previously a consultant to the Re:Mission study sponsor (Meda Pharma). Authors Kristoffer Hellstrand and Anna Martner have received honoraria and/or travel grants from the study sponsor. The other authors declare no potential conflicts of interest.
: The clinical phase IV trial (Re:Mission Trial, ClinicalTrials.gov; NCT01347996), was approved by the Regional ethical review board in Gothenburg on June 2, 2009, application number 267-09. All procedures of this study were performed in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All animal experiments were performed according to the institutional guidelines and approved by the Research Animal Ethics Committee in Gothenburg on April 4, 2014, application number 86-2014.
: Informed consent was obtained from all individual participants before enrollment to the phase IV AML Trial (Re:Mission Trial, ClinicalTrials.gov; NCT01347996).
: C57BL/6J and BALB/c mice were purchased from the Charles River Laboratories (Sulzfeld, Germany). B6.129S6-<i>Cybb</i><sup><i>tm1Din</i></sup> (<i>Nox2</i>- KO) mice were originally obtained from the Jackson Laboratory (Bar Harbor, ME, USA) and bred in-house.
: The EL-4 lymphoma cell line and the 4T1 mammary cancer cell line originated from the American Type Culture Collection (ATCC) and were provided by Ingo Schmitz (Otto von Guericke University, Germany) and Göran Landberg (University of Gothenburg, Sweden), respectively. The MC-38 colon carcinoma cell line originated from the Developmental Therapeutics Program Tumor Repository (Frederick National Laboratory, USA) and was provided by Sukanya Raghavan (University of Gothenburg, Sweden). All cell lines were expanded and frozen in aliquots and were cultured for no more than one week after thawing prior to use in in vivo experiments. Authentication by SNP or STR is not currently standardized for murine cell lines.